Clinical Trial Update: Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating rituximab plus combination chemotherapy with Y-90 ibritumomab tiuxetan in older patients with previously untreated B-cell lymphoma has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• Rituximab (rituximab)
• Yttrium-90 ibritumomab tiuxetan (yttrium-90 ibritumomab tiuxetan)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2020-11-12